ストックスクリーナーアプリを入手
1.23
3.36%
0.04
前日終値:
$1.19
開ける：
$1.21
24時間の取引高:
22,294
Relative Volume:
0.19
時価総額：
$15.13M
収益：
$31.56M
当期純損益:
$-46.89M
株価収益率:
-0.4056
EPS:
-3.0329
ネットキャッシュフロー:
$-26.70M
1週間 パフォーマンス:
-2.38%
1か月 パフォーマンス:
-28.07%
6か月 パフォーマンス:
-35.94%
1年 パフォーマンス:
-76.57%
1日の値動き範囲:
$1.17
$1.25
1週間の範囲:
$1.12
$1.268
52週間の値動き範囲:
$1.0909
$5.31
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
CASI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
1.23 | 24.45M | 31.56M | -46.89M | -26.70M | -3.0329 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 開始されました | Mizuho | Buy |
| 2020-10-23 | 開始されました | Oppenheimer | Outperform |
| 2016-09-22 | 開始されました | Maxim Group | Buy |
| 2015-10-29 | 再開されました | H.C. Wainwright | Buy |
| 2015-06-23 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Casi Pharmaceuticals Inc (CASI) 最新ニュース
How resilient is CASI Pharmaceuticals Inc. stock in market downturns2025 Key Lessons & Long-Term Capital Growth Strategies - newser.com
How CASI Pharmaceuticals Inc. stock performs in weak economyGap Up & Daily Growth Stock Tips - newser.com
How to read the order book for CASI Pharmaceuticals Inc.2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Is CASI Pharmaceuticals Inc. stock gaining market shareJuly 2025 Trends & Growth Oriented Trade Recommendations - newser.com
Is CASI Pharmaceuticals Inc. stock a top momentum playMarket Performance Summary & Weekly High Potential Alerts - newser.com
CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman - TipRanks
CASI Pharmaceuticals Announces Changes in Board Governance - Bluefield Daily Telegraph
CASI Pharmaceuticals (NASDAQ: CASI) appoints James Huang Non-Executive Chairman - Stock Titan
What MACD and RSI say about CASI Pharmaceuticals Inc.2025 Macro Impact & Fast Entry Momentum Alerts - newser.com
Smart tools for monitoring CASI Pharmaceuticals Inc.’s price actionTrade Analysis Summary & Safe Swing Trade Setups - newser.com
Is CASI Pharmaceuticals Inc. stock attractive for retirement portfoliosTrade Performance Summary & Consistent Profit Focused Trading Strategies - newser.com
Can CASI Pharmaceuticals Inc. stock resist sector downturnsBuy Signal & Expert Approved Momentum Trade Ideas - newser.com
Will CASI Pharmaceuticals Inc. stock attract more institutional investorsChart Signals & Capital Protection Trade Alerts - newser.com
CASI Pharmaceuticals Reports Q3 2025 Results Amid Nasdaq Delisting Appeal - MSN
CASI Pharmaceuticals Stumbles On Revenue Drop And Nasdaq Challenge - Finimize
Casi Pharmaceuticals Q3 revenue drops 60%, net loss widens - MarketScreener
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results - ACCESS Newswire
CASI Pharmaceuticals (NASDAQ: CASI) reports third-quarter revenue $3.1M; net loss $10.9M - Stock Titan
CASI Pharmaceuticals (CASI) Projected to Post Quarterly Earnings on Friday - Defense World
CASI Pharmaceuticals, Inc. (CASI) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
CASI Pharmaceuticals Appeals Nasdaq Delisting Determination - MSN
CASI Pharmaceuticals faces Nasdaq delisting over market value requirement By Investing.com - Investing.com Nigeria
CASI Pharmaceuticals faces Nasdaq delisting over market value requirement - Investing.com
CASI Pharmaceuticals : Receives and Appeals Delisting Determination from NASDAQ - MarketScreener
[6-K] CASI Pharmaceuticals, Inc. Current Report (Foreign Issuer) | CASI SEC FilingForm 6-K - Stock Titan
CASI Pharmaceuticals appeals NASDAQ delisting determination - MSN
Casi Pharmaceuticals Inc (CASI) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):